Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience
Why the study?
ATTR-CM is considered a contraindication to cardiac transplantation in some centers, partly due to a perceived risk of allograft amyloid recurrence.
Does cardiac transplantation improve survival in patients with transthyretin cardiac amyloidosis compared to non-transplanted patients?
Comparison
Cardiac transplantation vs non-transplanted ATTR-CM cohort
Design
Retrospective cohort study
Follow-up
Median 66 months
Authors
Discussion
Loading...
Member takes
Implication
Favorable long-term CT outcomes in ATTR-CM may challenge current contraindications; larger studies needed to confirm allograft safety.
Structured PICO
Does cardiac transplantation improve survival in patients with transthyretin cardiac amyloidosis compared to non-transplanted patients?
P
Population
14 patients with transthyretin cardiac amyloidosis (ATTR-CM) (11 wild-type, 3 variant), median age 62 years, 12 male, 2 female, evaluated across two tertiary centers.
I
Intervention
Cardiac transplantation
C
Comparator
Cohort of non-transplanted UK patients with ATTR-CM
O
Outcome
Survival (1, 3, and 5-year) and recurrence of amyloid in the cardiac allografthard clinical
Cardiac transplantation in patients with ATTR-CM yields excellent long-term survival with low risk of allograft amyloid recurrence, challenging the notion that ATTR-CM is a contraindication for transplant.
Cite This Study
Razvi et al. (2023) studied this question.